25th International AIDS Conference highlights potential of long-acting HIV prevention injections, with South Africa considering CAB-LA purchase despite cost concerns.
The 25th International AIDS Conference (AIDS 2024) saw excitement over the potential of long-acting antiretroviral formulations for HIV prevention, which don't require daily consumption. South Africa's health department is considering purchasing CAB-LA, a two-monthly anti-HIV injection, as it offers better adherence due to the reduced frequency of administration. However, the cost remains a significant concern, with the jab currently priced at four times more than the government pays for a two-month supply of the daily HIV prevention pill.
July 28, 2024
4 Articles